Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases DOI Creative Commons
Sathish Kumar Perumal, Madan Kumar Arumugam, Natalia A. Osna

et al.

Frontiers in Nutrition, Journal Year: 2025, Volume and Issue: 12

Published: March 24, 2025

Chronic liver disease is defined by persistent harm to the that might result in decreased function. The two prevalent chronic diseases are alcohol-associated (ALD) and metabolic dysfunction-associated steatotic (MASLD). There ample evidence pathogenesis of these closely linked gastrointestinal dysfunctions alters gut-liver crosstalk. These alterations mediated through imbalances gut microbiota composition/function combined with disruption barrier integrity allows for harmful microbes their toxins enter portal circulation reach elicit an inflammatory response. This leads further recruitment systemic cells, such as neutrophils, T-cells, monocytes into liver, which perpetuate additional inflammation development progressive damage. Many therapeutic modalities, currently used prevent, attenuate, or treat aimed at modulating dysbiosis improving intestinal Betaine a choline-derived metabolite methyl group donor antioxidant, anti-inflammatory osmoprotectant properties. Studies have shown low betaine levels associated higher organ been several publications demonstrating role supplementation preventing ALD MASLD. review explores protective effects its capacity regulate maintain prevent diseases. Further studies needed enhance our understanding potential could pave way targeted interventions management not only diseases, but other bowel conditions.

Language: Английский

Protection against Metabolic Associated Fatty Liver Disease by Protocatechuic Acid DOI Creative Commons
Jijun Tan, Ruizhi Hu,

Jiatai Gong

et al.

Gut Microbes, Journal Year: 2023, Volume and Issue: 15(1)

Published: July 28, 2023

Gut microbiota-diet interaction has been identified as a key factor of metabolic associated fatty liver disease (MAFLD). Recent studies suggested that dietary polyphenols may protect against MAFLD by regulating gut microbiota; however, the underlying mechanisms remain elusive. We first investigated effects cyanidin 3-glucoside and its phenolic metabolites on high-fat diet induced in C57BL/6J mice, protocatechuic acid (PCA) showed significant positive effect. Next, regulation PCA lipid metabolism microbiota were explored mouse model fecal transplantation (FMT) experiment. Dietary reduced intraperitoneal hepatic fat deposition with lower levels transaminases (AST & ALT) inflammatory cytokines (IL-1β, IL-2, IL-6, TNF-α MCP-1), but higher HDL-c/LDL-c ratio. Characterization indicated decreased Firmicutes/Bacteroidetes ratio mainly reducing relative abundance genus Enterococcus, which was positively correlated LDL-c, AST, ALT most up-regulated lipids lipidomics analysis. FMT experiments Enterococcus faecalis caused inflammation, insulin resistance expression carnitine palmitoyltransferase-1 alpha (CPT1α), can be reversed through inhibiting faecalis. Transcriptomics analysis decrease fibroblast growth 1 (Fgf1), recovered Fgf1 insulin-like binding protein 2 (Igfbp2), receptor substrate (Irs1) (Irs2). These results demonstrated high proportion accelerates CPT1α Fgf1, prevented supplementation PCA.

Language: Английский

Citations

48
Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial DOI Creative Commons
Mohamed El‐Kassas,

Hala Mostafa,

Wessam Abdellatif

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 2, 2025

The laxative lubiprostone has been shown to decrease intestinal permeability. We aimed assess the safety and efficacy of administered for 48 weeks in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Language: Английский

Citations

4
The crucial function of gut microbiota on gut-liver repair DOI Creative Commons
Yamei Wang,

Yan He,

Qianqian Zheng

et al.

hLife, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

2
Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis DOI Open Access
Roman Maslennikov, Elena Poluektova, O. Yu. Zolnikova

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(22), P. 16502 - 16502

Published: Nov. 19, 2023

Cirrhosis is the end result of liver fibrosis in chronic diseases. Studying mechanisms its development and developing measures to slow down regress it based on this knowledge seem be important tasks for medicine. Currently, disorders gut–liver axis have great importance pathogenesis cirrhosis. However, gut dysbiosis, which manifests as increased proportions microbiota Bacilli Proteobacteria that are capable bacterial translocation a decreased proportion Clostridia strengthen intestinal barrier, occurs even at pre-cirrhotic stage disease. This leads translocation, process by those microbes enter blood portal vein then tissue, where they activate Kupffer cells through Toll-like receptor 4. In response, produce profibrogenic cytokines, hepatic stellate cells, stimulating their transformation into myofibroblasts collagen other elements extracellular matrix. Blocking with antibiotics, probiotics, synbiotics, methods could progression fibrosis. was shown number animal models but requires further verification long-term randomized controlled trials humans.

Language: Английский

Citations

28
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk DOI Open Access
Keungmo Yang, Myeong Jun Song

Nutrients, Journal Year: 2023, Volume and Issue: 15(18), P. 3970 - 3970

Published: Sept. 14, 2023

Metabolism-associated fatty liver disease (MAFLD) is a multifaceted that involves complex interactions between various organs, including the gut and heart. It defined by hepatic lipid accumulation related to metabolic dysfunction, obesity, diabetes. Understanding intricate interplay of gut–liver–heart crosstalk crucial for unraveling complexities MAFLD developing effective treatment prevention strategies. The gut–liver participates in regulation inflammatory processes through host–microbiome interactions. Gut microbiota have been associated with development progression MAFLD, its dysbiosis contributes insulin resistance, inflammation, oxidative stress. Metabolites derived from enter systemic circulation influence both heart, resulting axis playing an important role MAFLD. Furthermore, growing evidence suggests endothelial inflammation may contribute increased risk cardiovascular (CVD). Additionally, dysregulation metabolism also lead cardiac dysfunction heart failure. Overall, molecular pathways CVD patients This review emphasizes current understanding as foundation optimizing patient outcomes

Language: Английский

Citations

23
From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences DOI Creative Commons
Ahmed Samy,

Mohamed A. Kandeil,

Dina Sabry

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(9), P. e30387 - e30387

Published: April 25, 2024

Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic diseases worldwide in recent decades. Metabolic like excessive blood glucose, central obesity, dyslipidemia, hypertension, and function abnormalities cause NAFLD. NAFLD significantly increases likelihood cancer, heart disease, mortality, making it a leading transplants. steatohepatitis (NASH) is more advanced form that causes scarring inflammation over time can ultimately result cirrhosis hepatocellular carcinoma. In this review, we briefly discuss NAFLD's pathogenic mechanisms, their progression into NASH afterward to NASH-related cirrhosis. It also covers epidemiology, metabolic glucose lipid metabolism liver, macrophage dysfunction, bile acid toxicity, stellate cell stimulation. Additionally, consider contribution intestinal microbiota, genetics, epigenetics, ecological factors fibrosis carcinoma risk patients.

Language: Английский

Citations

15
Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework DOI
Senlin Wang, Ruimin Zhang, Peisen Guo

et al.

The EPMA Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

Language: Английский

Citations

1
Distinct Gut Microbial Signature and Host Genetic Variants in Association with Liver Fibrosis Severity in Patients with MASLD DOI Open Access
Nantawat Satthawiwat,

Thananya Jinato,

Sawannee Sutheeworapong

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(12), P. 1800 - 1800

Published: June 7, 2024

Gut microbiota might affect the severity and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to characterize gut dysbiosis clinical parameters regarding fibrosis stages assessed by magnetic resonance elastography. This study included 156 patients with MASLD, stratified into no/mild (F0–F1) moderate/severe (F2–F4). Fecal specimens were sequenced targeting V4 region 16S rRNA gene analyzed using bioinformatics. The genotyping PNPLA3, TM6SF2, HSD17B13 was allelic discrimination assays. Our data showed that microbial profiles between groups significantly differed in beta-diversity but not alpha-diversity indices. Enriched Fusobacterium Escherichia_Shigella, depleted Lachnospira found F2–F4 group versus F0–F1 group. Compared F0–F1, had elevated plasma surrogate markers epithelial permeability bacterial translocation. genera, PNPLA3 polymorphisms, old age, diabetes independently associated advanced multivariable analyses. Using Random Forest classifier, signature three genera could differentiate high diagnostic accuracy (AUC 0.93). These results indicated imbalance enriched pathogenic decreased beneficial bacteria, association several genetic factors, potential contributors pathogenesis MASLD.

Language: Английский

Citations

8
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus DOI
Monika Bhardwaj, Papiya Mitra Mazumder

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: June 11, 2024

Language: Английский

Citations

7
Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives DOI

Janitha M. Unagolla,

Subarna Das,

Riley Flanagan

et al.

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 660, P. 124381 - 124381

Published: June 24, 2024

Language: Английский

Citations

6